Outset Medical Secures $40M HCA Contract for Tablo Hemodialysis Systems Refresh
Summary
Outset Medical secured a major $40 million contract with HCA to refresh and potentially expand its Tablo Hemodialysis Systems fleet through 2028, providing significant revenue visibility for the company.
Key Events
-
Major Contract Awarded
Outset Medical entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, L.P.
-
Significant Revenue Commitment
The agreement is valued at approximately $40 million, net of rebates and allowances, for purchases spanning from 2026 through the end of 2028.
-
Reinforces Key Partnership
HCA will refresh its existing fleet of Tablo Hemodialysis Systems, indicating continued adoption and trust in Outset Medical's technology.
-
Future Growth Framework
The agreement also establishes a purchase framework supporting potential future growth beyond the HCA hospitals that have already adopted the Tablo system.
Analysis
This filing announces a significant $40 million contract with HCA Management Services, L.P. for the refresh and potential expansion of Tablo Hemodialysis Systems through 2028. For a company with a market capitalization of approximately $74 million, this multi-year agreement represents a substantial revenue commitment and provides critical long-term visibility. It reinforces a key customer relationship and signals continued demand for Outset Medical's core product, which is vital for its financial stability and growth trajectory.
At the time of this filing, OM was trading at $4.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $74.4M. The 52-week trading range was $3.00 to $21.36. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.